LONDON, UK I1, 2024 I Vicebio Ltd ("Vicebio"), a biopharmaceutical company pioneering next-generation vaccines for life-threatening respiratory ...
BOSTON, MA, USA I, 2024 I LAPIX Therapeutics, Inc. (“LAPIX”), a clinical-stage biopharmaceutical company focused on developing novel, orally ...
MELBOURNE, Australia I November 19, 2024 I Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) (“Neurizon” or “the Company”), a clinical-stage biotech company advancing treatments for neurodegenerative ...
NKTR-422 demonstrated inflammation resolution and tissue repair in multiple preclinical models of chronic inflammatory conditions - ...
HAYWARD, CA, USA I1, 2024 I Avirmax Biopharma, Inc., a leader in the development of innovative gene therapies, today announced that the first ...
OXFORD, UK I November 19, 2024 I Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, has dosed the first patient in its Phase I/IIa multi-centre, ...
AURORA, CO, USA I November 21, 2024 I OncoVerity, a pioneer in applying advanced bioinformatics to drug development, announced today the closing of a Series A extension financing led by existing ...
Muvalaplin, an oral, once-daily treatment that inhibits lipoprotein(a) formation via a novel mechanism, achieved positive results in a 12-week Phase 2 study These data were published in the Journal of ...
Collaboration will combine Vyriad's lentiviral vector platform and Novartis expertise and leadership in cell therapy innovation ...
GIGA-2339 contains more than 1,000 fully human recombinant anti-HBV antibodies and is the first recombinant polyclonal therapeutic in development to treat and functionally cure chronic HBV infection ...
Investigational subcutaneous pembrolizumab and berahyaluronidase alfa, in combination with chemotherapy, demonstrates noninferior pharmacokinetics compared to intravenous KEYTRUDA in combination with ...